Abstract Microglial activation participates in the pathogenesis of various neuroinflammatory and neurodegenerative diseases. However, mechanisms by which microglial activation could be controlled are poorly understood. Peroxisome proliferator-activated receptors (PPAR) are transcription factors belonging to the nuclear receptor super family with diverse effect. This study underlines the importance of PPARb/d in mediating the anti-inflammatory effect of gemfibrozil, an FDA-approved lipid-lowering drug, in primary human microglia. Bacterial lipopolysachharides (LPS) induced the expression of various proinflammatory molecules and upregulated the expression of microglial surface marker CD11b in human microglia. However, gemfibrozil markedly suppressed proinflammatory molecules and CD11b in LPS-stimulated microglia. Human microglia expressed PPAR-b and -c, but not PPARa. Interestingly, either antisense knockdown of PPAR-b or antagonism of PPAR-b by a specific chemical antagonist abrogated gemfibrozil-mediated inhibition of microglial activation. On the other hand, blocking of PPAR-a and -c had no effect on gemfibrozil-mediated anti-inflammatory effect in microglia. These results highlight the fact that gemfibrozil regulates microglial activation by inhibiting inflammatory gene expression in a PPAR-b dependent pathway and further reinforce its therapeutic application in several neuroinflammatory and neurodegenerative diseases.
Introduction
Microglia, a resident macrophages and sensor cells of the CNS plays a key role in CNS remodeling and regeneration, and also act as a scavenger cells in the events of infection, inflammation, trauma, ischemia, and neurodegeneration in the CNS [14, 52] . Like macrophages, microglia respond to various stimuli by acquisition of a reactive phenotype as evidenced by the elevated expression of a number of cell surface molecules, including major histocompatibility complex class II antigens, CD45, complement receptors CR3 and CR4, immunoglobulin receptors FcGR1 and FcgR11, and intercellular adhesion molecule-1 [39, 53, 54] . Importantly, activated microglia also produce different type of soluble factors including cytokines (IL-1b, -6, TNF-a, and IL-12), NO, prostaglandins, and free oxygen radicals, which play an important role in host defense against CNS infections [2, 32, 54] . However, excessive production of these substances may accelerate the neuronal damage caused by several pathological conditions such as ischemic brain damage, trauma and neurodegenerative diseases. Several reports demonstrated the presence of activated microglia in pathological lesions in several neurological diseases including multiple sclerosis (MS); [32] , Alzheimer disease (AD) and Parkinson's disease (PD); [38] , and HIV-associated dementia (HAD) [16] .
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcriptional factors belonging to the socalled nuclear receptor family [12, 50] . To date, three different PPARs subtypes PPAR-a, -c and -b have been identified in vertebrates [4, 6, 12, 50] . PPARs can inhibit inflammatory gene expression by several mechanisms, including, competition for a limited pool of coactivators, direct interaction with p65 and p50 subunits and c-Jun, and modulation of p38 mitogen-activated protein kinase (MAPK) activity [11, 30, 31, 34, 44] . PPAR-b is ubiquitously expressed in different brain areas [41, 43, 48] . Although the exact function of PPAR-b is poorly defined, it is likely to play a critical role in cell proliferation, differentiation, survival, lipid metabolism, and development [7, 13, 20] . Even if not fully understood, the neuroprotective effect of PPAR-b agonists highlights their potential benefit to treat various acute or chronic neurological disorders.
Gemfibrozil (gem), an activator of PPAR-a, has been often prescribed in patients to lower the level of triglycerides [46, 55] . This drug decreases the risk of coronary heart disease by increasing the level of high density lipoprotein (HDL) cholesterol and decreasing the level of low density lipoprotein (LDL) cholesterol [22, 46] . Earlier we have demonstrated that gem inhibits the expression of inducible nitric oxide synthase in human astroglia independent of PPAR-a [42] . Accordingly, we have shown that gem suppresses the activation of mouse microglia independent of PPAR-a [24] and also inhibits the disease process of adoptively-transferred experimental allergic encephalomyelitis (EAE) independent of PPAR-a [10] . Others have also reported the anti-inflammatory effect of gem in other cells [57] [58] [59] .
While gem does not require PPAR-a for its antiinflammatory activity in glial cells, the receptor that could be involved for this remained elusive. Here we demonstrate that PPAR-b, but not PPAR-a and -c, is actually involved in anti-inflammatory activity of gem in primary human microglia.
Materials and Methods
Reagents FBS and DMEM/F-12 were obtained from Invitrogen Life Technologies. LPS (Escherichia coli), gemfibrozil, and fenofibrate were obtained from Sigma-Aldrich. GW501516 (PPAR-b agonist) and GW1929 (PPAR-c agonist) were purchased from Alexis Biochemical's. GSK0660 (PPAR-b antagonist), GW6471 (PPAR-a antagonist) and GW9662 (PPAR-c antagonist) were purchased from SigmaAldrich. PPAR-b antibody was purchased from Santa Cruz Biotecnol. Phosphorothioate-labeled antisense and scrambled oligodeoxynucleotides were synthesized in the DNAsynthesizing facility of Invitrogen. Following antisense (ASO) and scrambled (ScO) oligoneucleotides for different PPAR genes were used. 
Isolation of Primary Human Microglia and Astrocytes
Primary human microglia and astrocytes were prepared as described previously [25] . All of the experimental protocols were reviewed and approved by the Institutional Review Board of the Rush University Medical Center. Briefly, 11-to 17-week-old fetal brains obtained from the Human Embryology Laboratory (University of Washington, Seattle, WA, USA) were dissociated by trituration and trypsinization (0.25 % trypsin in PBS at 37°C for 15 min).
The trypsin was inactivated with 10 % heat-inactivated FBS (Mediatech, Washington, DC, USA). The dissociated cells were filtered successively through 380 and 140 lm meshes (Sigma, St. Louis, MO, USA) and pelleted by centrifugation. The cell pellet was washed once with PBS and once with Neurobasal media containing 2 % B27 and 1 % antibiotic-antimycotic mixture (Sigma). In the first step, neurons were allowed to adhere to poly-D-lysinecoated plates for 5 min. Non-adherent cells were cultured on poly-D-lysine precoated 75 cm 2 flasks and incubated at 37°C with 5 % CO 2 in air. Culture medium was changed after 3 days and every 3 days thereafter. On 9th day, flasks were placed on a rotary shaker at 240 rpm at 37°C for 2 h to remove loosely attached microglia. On 11th day, flasks were shaken again at 180 rpm for 18 h to remove oligodendroglia. Remaining adherent cells were astrocytes.
Immunostaining
Immunostaining was performed as described earlier [25, 28, 29] . Briefly, coverslips containing 200-300 cells/mm 2 were fixed with 4 % paraformaldehyde for 15 min, followed by treatment with cold ethanol (-20°C) for 5 min and two rinses in PBS. Samples were blocked with 3 % BSA in PBS containing Tween 20 (PBST) for 30 min and incubated in PBST containing 1 % BSA and primary antibody (1:50). After three washes in PBST (15 min each), slides were further incubated with Cy5 and Cy2 (Jackson Immuno Research, West Grove, PA, USA). For negative controls, a set of culture slides was incubated under similar conditions without the primary antibodies. The samples were mounted and observed under a Bio-Rad (Hercules, CA, USA) MRC1024ES confocal laser-scanning microscope.
Semi-quantitative RT-PCR Analysis
Total RNA was isolated from human primary microglia and astrocytes using RNA-Easy Qiagen kit following the manufacturer's protocol. To remove any contaminating genomic DNA, total RNA was digested with DNase. Semiquantitative reverse transcriptase-coupled (RT)-PCR was performed as described previously [24] using oligo (dT) [12] [13] [14] [15] [16] [17] [18] as primer and moloney murine leukemia virus reverse transcriptase (Clontech) in a 20 ll reaction mixture. The resulting cDNA was appropriately diluted, and diluted cDNA was amplified using titanium Taq polymerase and the following primers for human proinflammatory genes: tumor necrosis factor-a (TNF-a), sense, 0 -GTG AAG ACG CCA GTG GAC TC-3 0 . Amplified products were electrophoresed on a 1.8 % agarose gels and visualized by ethidium bromide staining. Message for the GAPDH gene was used to ascertain that an equivalent amount of cDNA was synthesized from different samples.
Real-Time PCR Analysis
It was performed using theABI-Prism7700 sequence detection system (Applied Biosystems, Foster City, CA, USA) as described earlier [9, 23, 27] . Briefly, it was performed in a 96-well optical reaction plate (Applied Biosystem) on cDNA equivalent to 50 ng DNase-digested RNA in a volume of 25 ll, containing 12.5 ll TaqMan Universal Master Mix and optimized concentrations of FAM-labeled probe, forward and reverse primers following the manufacturer's protocol. All primers and FAM-labeled probes for human CD11b, IL-6, iNOS, LT-a, and GAPDH were obtained from Applied Biosytems. The mRNA expression of pro-inflammatory genes was normalized to the label of GAPDH mRNA. Data were processed by the ABI sequence detection system 1.6 software and analyzed by ANOVA.
Statistical Analysis
All values are expressed as the mean ± SD of three independent experiments. Statistical differences between means were calculated by Student's t test. A p value of \0.05 (p \ 0.05) was considered statistically significant.
Results

Gemfibrozil (Gem) Inhibits LPS-Induced Expression of iNOS and Proinflammatory Cytokines in Primary Human Microglia
Microglia isolated from human fetal brain tissues were highly pure and contained 1-2 % astroglia (Fig. 1a ), but no oligodendroglia (Fig. 1b) and neurons (Fig. 1c) . To determine the effect of gemfibrozil on the activation of human microglia, microglia were exposed to different concentrations of gemfibrozil (50-200 lm) for 2 h, followed by treatment with LPS for 6 h and RNA was harvested for semi-quantitative RT-PCR. As expected, LPS markedly induced mRNA expression of iNOS and different proinflammatory cytokines (TNF-a, IL-1b, -1a, -6, Lt-a, IL-15, and IL-18) in human microglia (Fig. 1d) . Although gemfibrozil itself was neither stimulatory nor much inhibitory to the expression of proinflammatory molecules in control microglia (data not shown), this drug dose-dependently reduced LPS-induced expression of iNOS and proinflammatory cytokines in microglia (Fig. 1d) .
To investigate whether other fibrate drugs are also capable of suppressing the expression of proinflammatory molecules in human microglia, we examined the effect of clofibrate. Clofibrate is also a hypolipidemic drug that activates PPAR-a and induces the proliferation of peroxisomes in rats and mice [33] . Similar to gemfibrozil, clofibrate also inhibited the expression of different proinflammatory molecules (TNF-a, IL-1b, -1a, -6, Lt-a, IL-15, and -18) in LPS-stimulated primary human microglia (Fig. 1e) . However, clofibrate was less potent than gemfibrozil in suppressing the mRNA expression of proinflammatory molecules (Fig. 1d, e) . These results suggest that fibrate drugs, in general, are inhibitory to LPSinduced expression of different proinflammatory molecules in primary human microglia.
Gemfibrozil Suppresses CD11b Expression in Human Microglia
Microglia are derived from a monocytic lineage and act functionally as macrophages in the brain [2] . Microglia can Fig. 1 Effects of gemfibrozil on LPS induced proinflammatory gene expression. To examine the purity of microglia, cells were double-immunolabeled with CD11b and either GFAP, GalC, or MAP-2 and observed under a confocal laser-scanning microscope (a-c). Human primary microglia was pretreated with gemfibrozil 2 h before LPS (1 lg/ml) treatment. At 6 h after LPS treatment, total RNA was isolated and analyzed by semi quantitative RT-PCR (d). Human primary microglia was pretreated with clofibrate (100 lM) 2 h before LPS (1 lg/ ml) treatment. After 6 h of treatment, total RNA was isolated and analyzed by semi quantitative RT-PCR (e). The gel shown was one representative of results from three separate experiments be activated by secretary substances or signals associated with disease or injury, and become a phagocytic cell which also produces its own injurious molecules. In the activating process, its morphology is changed from a resting processbearing cell (ramified form) into a rounded amoebic form displaying new or increased amounts of functional markers, such as cell surface receptors and classes I and II MHC molecules. Increased expression of the b2-integrin CD11b/ CD18 (MAC-1) has been also reported in either plaqueassociated microglia in the AD brain or lesion-associated microglia in MS brain [40] . It has been also shown that LPS treatment of primary microglia results in morphological changes as well as increased expression of CD11b immunoreactivity [21, 45] . We investigated if gemfibrozil was capable of down-regulating CD11b in LPS-stimulated primary human microglia. As expected, LPS markedly increased the mRNA expression of CD11b in microglia (Fig. 2a, b) . However, gemfibrozil pretreatment markedly suppressed LPS-induced mRNA expression of CD11b (Fig. 2a, b) . Immunofluorescence analysis of CD11b in primary microglia also shows that LPS stimulation increased the expression of CD11b and that gemfibrozil attenuated LPS-mediated CD11b expression (Fig. 2c) . Similarly, clofibrate also inhibited LPS induced CD11b mRNA expression in primary human microglia (Fig. 2d,  e ). These data demonstrate that gemfibrozil and clofibrate are capable of inhibiting cellular activities responsible for activation and phenotypic conversion of human microglia.
Primary Human Microglia Express PPAR-c and -b, But Not PPAR-a Next we investigated mechanisms by which gem inhibited the proinflammatory gene expression in human microglia. Gemfibrozil, a known agonist of PPAR-a, stimulates the b-oxidation of fatty acids in peroxisomes and mitochondria via the activation of PPAR-a [1] . At first, we analyzed the level of different PPARs in cultured microglia and astrocytes. However, despite several attempts, we remained unable to detect the expression of PPAR-a mRNA in primary human microglia (Fig. 3a) and astroglia (Fig. 3c) by semi-quantitative RT-PCR. Interestingly, LPS decreased the mRNA expression of PPAR-b compared to control and gemfibrozil treatment markedly increased the level of PPAR-b in LPS-stimulated microglia (Fig. 3a, b) and astroglia (Fig. 3c, d) . Consistent with the mRNA analysis, evaluation of PPAR-b protein expression in microglia also revealed an increase in PPAR-b expression in LPS-stimulated microglia by gemfibrozil treatment (Fig. 3e) . In contrast to the decrease in PPAR-b expression, LPS stimulation markedly increased the mRNA expression of PPAR-c in microglia (Fig. 3a) and astroglia (Fig. 3c) . Interestingly, gemfibrozil decreased the mRNA expression of PPAR-c in microglia and astroglia, which is also in contrast to the effect of this drug on PPAR-b (Fig. 3a-d) .
Immunofluorescence analysis also show that LPS decreased the level of PPAR-b (Fig. 3e) , while increasing the level of PPAR-c (Fig. 3f) in human microglia.
Gem Inhibits the Expression of Proinflammatory Molecules (IL-6 and iNOS) in Primary Human Microglia Via PPAR-a-Independent Mechanism
By overexpressing wild-type and dominant-negative constructs of PPAR-a in microglial cells and isolating primary microglia from PPAR-a (-/-) mice, we have recently demonstrated that gemfibrozil inhibits the activation of microglia independent of PPAR-a [24, 42] . Although we could not detect PPAR-a in human microglia by RT-PCR (Fig. 3) , these cells may contain low level of PPAR-a that could be sufficient for mediating the anti-inflammatory effect of gem. Therefore, here we decided to investigate if gem required PPAR-a to suppress proinflammatory molecules in human microglia. Phosphorothioate-labeled antisense oligonucleotides provide an important option to knockdown specific gene in primary non-dividing cells without causing any cell death, which is always observed in transfection experiments. Therefore, we employed antisense oligonucleotides to knockdown PPAR-a in primary human microglia. Antisense knockdown of PPAR-a failed to abrogate the inhibitory effect of gem on the expression of iNOS and IL-6 in LPS-stimulated human microglia (Fig. 4a) . To further confirm this result, we also treated microglia with PPAR-a antagonist (GW6471). As evident from Fig. 4b , GW6471 remained unable to block the inhibitory effect of gem on LPS-induced expression of IL-6 and iNOS in human microglia. These results clearly suggest that gem does not require PPAR-a to inhibit the expression of proinflammatory genes in primary human microglia.
Gem Inhibits the Expression of Proinflammatory Molecules in Primary Human Microglia Via PPAR-b, But Not PPAR-c
Next, we investigated the role of PPAR-b and -c in gemmediated inhibition of pro-inflammatory gene expression. Therefore, we employed antisense oligonucleotides to knockdown PPAR-b, and -c in primary human microglia. Interestingly, antisense knockdown of PPAR-b markedly suppressed the inhibitory effect of gem on the expression of pro-inflammatory molecules in LPS-stimulated human microglia (Fig. 5a, b) . These results were specific as scrambled oligonucleotides (ScO) remained unable to influence the anti-inflammatory effect of gem. Immunofluorescence analysis also shows that ASO, but not ScO, abrogated the inhibitory effect of gem on LPS-induced expression of iNOS protein (Fig. 5c) . In contrast to antisense knockdown of PPAR-b, ASO against PPAR-c had no effect on gem-mediated inhibition of iNOS in microglia (Fig. 5d) . These results suggest that gem exhibits antiinflammatory effect in human microglia via PPAR-b.
Effect of PPAR-b and -c Antagonist on LPS Induced iNOS and Pro-inflammatory Gene Expression in Primary Human Microglia
To further bolster these results that gemfibrozil suppresses the expression of pro-inflammatory molecules via PPAR-b, but not PPAR-c, in human microglia, cells were treated with either PPAR-b or -c antagonist in the presence or absence of gem. As evident from semi-quantitative RT-PCR (Fig. 6a) and quantitative real-time PCR (Fig. 6b) , GSK3787, a specific antagonist of PPAR-b, markedly abrogated gem-mediated inhibition of Lt-a, iNOS and IL-6 in human microglia, confirming the involvement of PPARb in anti-inflammatory effect of gem in human microglia. Furthermore, we observed that gem and GW501519, a specific PPAR-b agonist, remained unable to inhibit the expression of pro-inflammatory molecules (Lt-a, iNOS and IL-6) in the presence of GSK3787 (Fig. 6c, d ). On the other hand, PPAR-c agonist GW1929 inhibited the LPS-induced the expression of proinflammatory molecules in presence of PPAR-b antagonist (GSK3787) in human primary microglia (Fig. 6b, d ), demonstrating the specificity of the effect. Moreover, we observed that gem inhibited the expression of pro-inflammatory molecules (Lt-a, iNOS and IL-6) in the presence of GW9662, a PPAR-c antagonist, in human microglia (Fig. 6e, f) . These results demonstrate that gem inhibits the LPS-induced proinflammatory molecule expression via PPAR-b, but not PPAR-c, in human microglia.
Discussion
Common pathological hallmarks of several neurodegenerative diseases include the loss of invaluable neurons associated with or followed by massive activation of microglia. Although microglial activation has an important repairing function, once microglia is activated in the neurodegeneration microenvironment, it always goes beyond control and eventually detrimental effects override beneficial effects. Therefore, understanding mechanisms that Fig. 4 Effect of PPAR-a antisense knockdown on LPS inducediNOS production in human primary microglia. Human primary microglia received either ASO or ScO at 1 lM against PPAR-a, after 40 h of incubation, the cells were pretreated with gemfibrozil 2 h before LPS (1 lg/ml) treatment. At 6 h after LPS treatment, total RNA was isolated and analyzed by semi quantitative RT-PCR (a). Cells were simultaneously pretreated with gemfibrozil and GW6471 (PPAR-a antagonist) 2 h before LPS (1 lg/ml) treatment. At 6 h after LPS treatment, total RNA was isolated and assessed by semi quantitative RT-PCR (b). Results represent three independent experiments regulate microglial activation is an important area of investigation that may enhance the possibility of finding a primary or an adjunct therapeutic approach against incurable neurodegenerative disorders.
The studies reported in this manuscript clearly demonstrate that gemfibrozil, a commonly used lipid-lowering drug and an activator of PPAR-a, suppresses the expression of pro-inflammatory molecules (iNOS, TNF-a, IL-1b, and -6) in human primary microglia. Because these proinflammatory molecules have been implicated in the pathogenesis of demyelinating and neurodegenerative diseases, our results provide a potentially important mechanism whereby activators of PPAR-a may ameliorate neural injury. Although gemfibrozil exerted anti-inflammatory effect in LPS-stimulated human microglia upon 2 h preincubation, it should not be a problem in chronic neuroinflammatory and neurodegenerative disorders, which are associated with consistent generation of proinflammatory molecules. Therefore, in such conditions, gemfibrozil treatment is expected to suppress subsequent cycles of proinflammatory signaling pathways. Accordingly, we [10] and others [19, 37] have shown that gemfibrozil is capable of suppressing the progression of relapsing-remitting and chronic EAE in mice. Earlier we have demonstrated that DhPPAR-a (a dominant-negative mutant of human PPARa) is unable to block the inhibitory effect of gemfibrozil on the induction of iNOS in human astroglia, suggesting that gemfibrozil does not require PPAR-a to inhibit the induction of iNOS in human astroglia [42] . Although one study by Xu et al. [58] has indicated the possible involvement of PPAR-a in gemfibrozil-mediated inhibition of microglial iNOS, this study does not attempt to examine the effect of gemfibrozil in PPAR-a (-/-) microglia. Recently, by using microglia from wild type and PPAR-a (-/-) mice, we have demonstrated that gemfibrozil inhibits the activation of mouse microglia without involving PPAR-a [24] . However, the nuclear receptor that was involved in antiinflammatory efficacy of gemfibrozil in microglia was not known.
Here we demonstrate that gemfibrozil inhibits the induction of proinflammatory gene expression in human microglia via PPAR-b, but not PPAR-a and -c. This conclusion is based on the following observations. First PPAR-a was present in primary human microglia at an undetectable level. Gemfibrozil was also unable to stimulate the level of PPAR-a in microglia. Second although gemfibrozil is a known activator of PPAR-a, either antisense knockdown of PPAR-a or antagonism PPAR-a by pharmacological drug did not block the anti-inflammatory effect of gemfibrozil. Third fibrate drugs like clofibrate is more selective for PPAR-a than either PPAR-b or -c [3, 15] . Accordingly, clofibrate was less potent in suppressing the mRNA expression of various proinflammatory molecules in human microglia. Fourth human microglia [49, 60] . Similarly, siRNA knockdown of PPAR-b leads to an increase in PPAR-c activation in colon cancer cells [60] . Therefore, these findings are consistent with our result that upregulation of PPAR-b by gemfibrozil leads to the down-regulation of PPAR-c in primary human microglia. However, the precise mechanism by which PPAR-b inhibits the expression of PPAR-c in human microglia requires further investigation.
Mechanisms by which PPAR-b could be coupled to proinflammatory gene expression are poorly understood. Among all the known proinflammatory transcription factors working in concert to transactivate promoters of proinflammatory genes, NF-jB p50:p65 is literally the most important one [17] . The presence of multiple consensus sequences (jB elements) in the promoter region of proinflammatory molecules for the binding of NF-jB and the inhibition of proinflammatory gene expression in human, rat, and mouse glial cells with the inhibition of NF-jB activation [5, 8, 17, 18, 26, 36, 47, 56] establishes an essential role of NF-jB activation in the induction of proinflammatory molecules. Previous studies have provided evidence that PPAR can inhibit inflammatory gene expression by several mechanisms, including competition for a limiting pool of coactivators, direct interaction with NF-jB p65 and p50 subunits, modulation of p38 MAPK activity, and partitioning the corepressor B-cells lymphoma 6 (BCL-6) [11, 30, 31, 35, 44] . Compared to PPAR-a and -c, relatively little is known on the role of PPAR-b in the regulation of inflammatory responses [44] . Gemfibrozil induced-PPAR-b may suppress the activation of NF-jB by different models. In the direct interaction model, PPAR-b may be actively exported from the nucleus into the cytosol by interaction with NF-jB, leading to an alteration in the expression of proinflammatory genes such as IL-6, iNOS and IL-1b in human microglia. In the second model, in the absence of a ligand, PPAR-b may sequester BCL-6 from inflammatory response genes, leading to an increased expression of proinflammatory molecules. In contrast, in the presence of a ligand (e.g. gemfibrozil), PPAR-b releases the repressor; which distributes to NFjB-dependent promoters and exerts anti-inflammatory effects by repressing the transcription of proinflammatory genes. The release of BCL-6 is known to contribute to many of the anti-inflammatory actions of PPAR-b in macrophages both in vitro [31, 51] and in vivo [51] . Although the role of BCL-6 in other tissues is not clear and we have not been able to analyze the role of BCL-6 in human microglia due to scarcity of primary human microglia, it is possible that gemfibrozil employs the PPAR-b-BCL-6 pathway in order to suppress the expression of proinflammatory molecules in human microglia.
In this study, we have used LPS as a prototype inducer of proinflammatory molecules, which may not be directly relevant to neurodegenerative disorders like AD, PD etc. However, similar to LPS, other inducers like IL-1b, amyloid-b peptides (an etiological reagent for AD) or MPP ? (an etiological reagent for PD) also activate glial cells via activation of NF-jB [24] . Because gem is capable of inhibiting the activation of NF-jB in mouse and human glial cells, this drug is expected to inhibit the activation of human microglia in response to disease-specific stimuli. In summary, we have demonstrated that gemfibrozil, an FDAapproved drug for hyperlipidemia, suppresses the activation of primary human microglia via PPAR-b. Although the in vitro situation of human fetal microglia in culture does not truly resemble the in vivo situation of microglia in the brain of patients with neurodegenerative disorders, our results suggest that specific modulation of PPAR-b by gemfibrozil may be an important therapeutic avenue to halt microglial activation in different neurodegenerative disorders.
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